Although normal or near-normal Hb levels in CKD patients were associated with reduced mortality in many observational studies [9–11], recent evidence from randomized clinical trials does not support a beneficial effect of Hb normalization on survival. This evidence concerns the gene GSTM1 and chronic kidney disease.